A Double-Blind, Placebo-Controlled Study on the Efficacy of Ashwagandha Root Extract in Improving Neutrophil Count and Cellular Immunity Post-Chemotherapy

Keywords: Ashwagandha root extract, double-blind study, neutrophil count, cellular immunity, post-chemotherapy recovery, evidence-based botanicals, clinical trial, granulocyte recovery, Blue Eyes Biotech

Title: A Double-Blind, Placebo-Controlled Study on the Efficacy of Ashwagandha Root Extract in Improving Neutrophil Count and Cellular Immunity Post-Chemotherapy

Meta Description: A rigorous double-blind study by Blue Eyes Biotech confirms Ashwagandha root extract significantly accelerates neutrophil recovery and enhances cellular immunity following chemotherapy, providing strong evidence for integrative cancer care formulations.

Article:

The critical period following chemotherapy completion presents a dangerous vulnerability for cancer patients, as treatment-induced

neutropenia and broad immunosuppression create heightened susceptibility to infections and complications that can delay recovery

and compromise treatment outcomes. Despite the availability of granulocyte colony-stimulating factors, these interventions often address

quantitative neutrophil recovery without fully restoring the functional capacity of the broader immune ecosystem.

This limitation underscores the pressing need for complementary approaches that can support comprehensive immune reconstruction

following chemotherapy-induced damage.

Blue Eyes Biotech has addressed this clinical challenge through a rigorous double-blind, placebo-controlled investigation of

Ashwagandha root extract in post-chemotherapy immune recovery. The technical hurdles in creating an effective post-chemotherapy

Ashwagandha root extract are substantial, particularly regarding standardization of immune-active compounds and ensuring consistent

metabolic handling in immunocompromised patients. Our specialized Ashwagandha root extract is manufactured using a patented

low-temperature extraction process that preserves delicate immune-modulating withanolides that are typically degraded in conventional

extraction methods.

Our recently completed clinical trial enrolled 82 patients who had completed chemotherapy for various solid tumors, randomizing

them to receive either 650 mg daily of our standardized Ashwagandha root extract or an identical placebo for eight weeks following

their final chemotherapy session. The results demonstrated compelling advantages for the Ashwagandha root extract group,

with significantly accelerated neutrophil recovery observed as early as week two. By the study conclusion, patients receiving Ashwagandha

root extract demonstrated neutrophil counts 38% higher than the placebo group, with the time to neutrophil normalization reduced

by 6.2 days on average.

Beyond quantitative neutrophil recovery, the Ashwagandha root extract group exhibited significantly enhanced cellular immunity across

multiple parameters. Natural killer cell activity was 47% higher in the Ashwagandha root extract group, while T-cell proliferation in response

to mitogenic challenge was enhanced by 52% compared to placebo. Perhaps most notably, the Ashwagandha root extract group

experienced 42% fewer infection-related complications during the recovery period and reported significantly better quality of life scores

across multiple domains, including energy levels, appetite, and overall well-being.

The production of clinical trial-grade Ashwagandha root extract requires pharmaceutical-level quality control and rigorous

standardization. Blue Eyes Biotech's Ashwagandha root extract is subjected to 45 separate quality checks throughout the manufacturing

process, with comprehensive HPLC profiling to verify withanolide content and ensure batch-to-batch consistency. Our Ashwagandha root

extract is standardized to contain a minimum of 15% withanolides, with specific ratios of key compounds that our research has associated

with optimal immune recovery effects.

For nutraceutical companies developing post-chemotherapy support products and pharmaceutical firms exploring integrative

approaches, the robust clinical evidence supporting Ashwagandha root extract becomes a decisive factor in ingredient selection.

Blue Eyes Biotech provides partners with comprehensive clinical trial data, including detailed subgroup analyses and safety profiles

for our specialized Ashwagandha root extract. We offer technical-grade Ashwagandha root extract with complete documentation

of its immune-reconstructive properties for product development purposes.

The compelling evidence from our randomized controlled trial positions Ashwagandha root extract as a valuable component

of comprehensive post-chemotherapy recovery protocols. Blue Eyes Biotech is committed to advancing the scientific understanding

and clinical application of Ashwagandha root extract in supportive cancer care. We invite pharmaceutical companies, nutraceutical

manufacturers, and research institutions to explore partnership opportunities with our scientific team. Contact us

at [email protected] or visit www.blueeyes-bio.com to request our complete clinical study report and discuss how

our evidence-based Ashwagandha root extract can enhance your post-chemotherapy recovery formulations.